Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 877 across all filing types
Latest filing 2017-05-15 Legal Proceedings Report
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical fortsätter kommunikationen med US Food and Drug Administration (FDA) angående väg mot marknadsgodkännande i USA
Legal Proceedings Report Classification · 99% confidence The document discusses ongoing communication and feedback received from the US Food and Drug Administration (FDA) regarding the regulatory pathway for the Episealer implant in the US market, specifically referencing a 513(g) Request for Information. This content relates to legal, regulatory, or compliance matters concerning market approval, which falls under the scope of legal proceedings or regulatory updates. Since it is an update on regulatory interaction rather than a formal financial report (like 10-K, IR, ER) or a general announcement of a report (RPA), and it specifically details interaction with a regulatory body (FDA) concerning market access, it best fits the 'Legal Proceedings Report' (LTR) category, as it details a significant regulatory/legal hurdle/process. Given the context of regulatory interaction and potential future applications, 'LTR' is the most appropriate fit among the specific options, although 'RNS' (Regulatory Filings) is a close fallback. I will classify it as LTR due to the specific nature of the FDA interaction being detailed.
2017-05-15 Swedish
Episurf Medical continues its communication with the US Food and Drug Administration (FDA) regarding appropriate route for market acceptance in the US
Legal Proceedings Report Classification · 99% confidence The document discusses ongoing communication between Episurf Medical and the US Food and Drug Administration (FDA) regarding regulatory pathways for market acceptance, specifically mentioning a 513(g) Request for Information and the expected decision timeline (Q3 2017). This content relates to legal, regulatory, or administrative proceedings involving the company and a government body (FDA). It is not a standard financial report (10-K, IR, ER), a management change announcement (MANG), or a shareholder vote result (DVA). Since it details significant legal/regulatory interaction concerning product approval, the most fitting category is Legal Proceedings Report (LTR), as it updates stakeholders on a significant regulatory/legal matter. The document length (2741 chars) is short, but it is a substantive update on a regulatory process, not merely an announcement that a report is attached (which would suggest RPA or RNS). Therefore, LTR is the best fit.
2017-05-15 English
OUTCOME OF EPISURF MEDICAL’S RIGHTS ISSUE
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 16, 2017, titled "OUTCOME OF EPISURF MEDICAL'S RIGHTS ISSUE." It details the subscription results (91.5% subscribed, raising approximately SEK 109.5 million) of a previously announced rights issue, including the resulting increase in share capital and the number of shares. This content directly relates to the company's fundraising and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), as it contains the substantive results of the financing event.
2017-03-16 English
UTFALL I EPISURF MEDICALS FÖRETRÄDESEMISSION
Share Issue/Capital Change Classification · 99% confidence The document is titled "UTFALL I EPISURF MEDICALS FÖRETRÄDESEMISSION" (Outcome of Episurf Medical's Rights Issue) and explicitly discusses the subscription period, the percentage subscribed (91.5%), the capital raised (approx. 109.5 million SEK), changes in share capital, and the expected registration dates. This content directly relates to a financing activity and capital structure change resulting from a rights issue. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release announcing the outcome, the core subject matter is the financing event itself, making CAP more specific than a general RPA or ER.
2017-03-16 Swedish
Episurf Medical AB to present at Aktiedagen, held in Stockholm on March 6
Report Publication Announcement Classification · 99% confidence The document is a short company announcement dated March 2, 2017, stating that Episurf Medical AB will present at an investor conference ('Aktiedagen') on March 6. It provides details about the event, the representative (acting CEO), and mentions that the presentation will be available on the company's website. Since the document is very short (1669 chars) and its primary function is to announce the *timing* and *occurrence* of a future presentation/event rather than being the presentation itself or a core regulatory filing (like 10-K or ER), it fits best under the category for announcing the publication or availability of company information or events. It is not an Investor Presentation (IP) because it is only an announcement *about* a presentation, not the presentation content itself. It is not a Regulatory Filing (RNS) because it fits a more specific category. The most appropriate classification is Report Publication Announcement (RPA), as it announces the upcoming presentation/event where information will be shared, similar to announcing the release of a report.
2017-03-02 English
Episurf Medical AB presenterar vid Aktiedagen den 6 mars i Stockholm
Regulatory Filings Classification · 90% confidence The document is a short press release dated March 2, 2017, announcing that Episurf Medical AB will present at an event called 'Aktiedagen' (Shareholder Day) on March 6th. It explicitly states that the presentation will be made available on the company's website. Since the document itself is an announcement about an upcoming presentation/event, and not the presentation material, the core function is announcing the availability or scheduling of company information/events. Given the short length (1614 chars) and the nature of announcing participation in an investor event, this fits best under Report Publication Announcement (RPA) if it were announcing a formal report, or more generally, a Regulatory Filing (RNS) if it doesn't fit elsewhere. However, since it is announcing participation in an investor-focused event where a presentation will be given, and the presentation itself is not included, it is an announcement of corporate activity. It is not a formal regulatory filing like 10-K or ER. It is closest to an announcement regarding investor relations activities. Given the options, and that it is a general press release about an upcoming investor presentation, RNS (Regulatory Filings - general/miscellaneous) is the most appropriate fallback, although it is very close to an Investor Presentation (IP) announcement, but it is not the presentation itself. Since it is a general press release announcing participation in an investor event, RNS is the safest general classification for non-standard announcements.
2017-03-02 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.